^
Association details:
| Biomarker: | IDH1 R132C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib
Published date:
09/14/2020
Excerpt:
...advanced NSCLC patients before dabrafenib and trametinib treatment were included...The two patients with a concurrent IDH1 p.(R132C) mutation had a complete response with a PFS of 32 months and an ongoing response of 12 months.
